**Supplementary Table S1.**Baseline differences between completers and missing at the end of treatment and at 6- and 12-month follow-up

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | End of treatment |   |   | 6-month follow-up |   |   | 12-month follow-up |   |   |
|   | Completers (n=102) | Missing (n=7) |   |   | Completers (n=95) | Missing (n=14) |   |   | Completers (n=84) | Missing (n=25) |   |   |
|   | # | % | # | % | *χ2* | *p* | # | % | # | % | *χ2* | *p* | # | % | # | % | *χ2* | *p* |
| Hispanic a | 11 | 10.80 | 0 | 0.00 | 0.84 | 0.36 | 9 | 9.50 | 2 | 13.30 | 0.31 | 0.58 | 7 | 8.30 | 4 | 16.00 | 1.25 | 0.26 |
| Race a |  |  |   |   | 0.88 | 0.83 |   |   |   |   | 0.32 | 0.96 |   |   |   |   | 1.10 | 0.78 |
| White | 74 | 72.50 | 6 | 85.70 |   |   | 69 | 72.60 | 11 | 78.60 |   |   | 63 | 75.00 | 17 | 68.00 |   |   |
| Black | 18 | 17.60 | 1 | 14.30 |   |   | 17 | 17.90 | 2 | 14.30 |   |   | 14 | 15.70 | 5 | 20.00 |   |   |
| Asian | 1 | 1.00 | 0 | 0.00 |   |   | 1 | 1.10 | 0 | 0.00 |   |   | 1 | 1.20 | 0 | 0.00 |   |   |
| Other | 9 | 8.80 | 0 | 0.00 |   |   | 8 | 8.40 | 1 | 7.10 |   |   | 6 | 7.10 | 3 | 12.00 |   |   |
| OBD abstinence b  | 19 | 18.60 | 0 | 0.00 | 1.58 | 0.21 | 19 | 20.00 | 0 | 0.00 | 3.39 | 0.07 | 16 | 19.00 | 3 | 12.00 | 0.67 | 0.42 |
| OBE abstinence b  | 19 | 18.60 | 0 | 0.00 | 1.58 | 0.21 | 19 | 20.00 | 0 | 0.00 | 3.39 | 0.07 | 16 | 19.00 | 3 | 12.00 | 0.67 | 0.42 |
| V abstinence  b  | 77 | 75.50 | 5 | 71.40 | 0.06 | 0.81 | 72 | 75.80 | 10 | 71.40 | 0.13 | 0.72 | 65 | 77.40 | 17 | 68.00 | 0.91 | 0.34 |
| BED / BN diagnosis b  | 73 | 71.60 | 5 | 71.40 | 0.00 | 0.99 | 68 | 71.60 | 10 | 71.40 | 0.00 | 0.99 | 61 | 72.60 | 17 | 68.00 | 0.20 | 0.65 |
| # Axis II disorders c |  |  |   |   | 8.98 | 0.06 |   |   |   |   | 11.23 | 0.02 |   |   |   |   | 7.85 | 0.10 |
| 0 | 68 | 66.70 | 4 | 57.10 |   |   | 64 | 67.40 | 8 | 57.10 |   |   | 52 | 61.90 | 20 | 80.00 |   |   |
| 1 | 19 | 18.60 | 0 | 0.00 |   |   | 19 | 20.00 | 0 | 0.00 |   |   | 19 | 22.60 | 0 | 0.00 |   |   |
| 2 | 13 | 12.70 | 2 | 28.60 |   |   | 10 | 10.50 | 5 | 35.70 |   |   | 11 | 13.10 | 4 | 16.00 |   |   |
| 3 | 1 | 1.00 | 1 | 14.30 |   |   | 1 | 1.10 | 1 | 7.10 |   |   | 1 | 1.20 | 1 | 4.00 |   |   |
| 4 | 1 | 1.00 | 0 | 0.00 |   |   | 1 | 1.10 | 0 | 0.00 |   |   | 1 | 1.20 | 0 | 0.00 |   |   |
| # Axis I disorders (lifetime) d |  |  |   |   | 2.42 | 0.49 |   |   |   |   | 4.73 | 0.19 |   |   |   |   | 3.39 | 0.34 |
| 0 | 67 | 65.70 | 5 | 71.40 |   |   | 62 | 65.30 | 10 | 71.40 |   |   | 53 | 63.10 | 19 | 76.00 |   |   |
| 1 | 20 | 19.60 | 1 | 14.30 |   |   | 20 | 21.10 | 1 | 7.10 |   |   | 18 | 21.40 | 3 | 12.00 |   |   |
| 2 | 11 | 10.80 | 0 | 0.00 |   |   | 10 | 10.50 | 1 | 7.10 |   |   | 10 | 11.90 | 1 | 4.00 |   |   |
| 3 | 4 | 3.90 | 1 | 14.30 |   |   | 3 | 3.20 | 2 | 14.30 |   |   | 3 | 3.60 | 2 | 8.00 |   |   |
| # ETOH & SUD disorders (current) d | 1 | 1.00 | 0 | 0.00 | 0.07 | 0.79 | 1 | 1.10 | 0 | 0.00 | 0.15 | 0.70 | 1 | 1.20 | 0 | 0.00 | 0.30 | 0.58 |
| # anxiety disorders (current) d |  |  |   |   | 0.99 | 0.80 |   |   |   |   | 1.49 | 0.68 |   |   |   |   | 0.79 | 0.85 |
| 0 | 71 | 69.60 | 6 | 85.70 |   |   | 67 | 70.50 | 10 | 71.40 |   |   | 58 | 69.00 | 19 | 76.00 |   |   |
| 1 | 23 | 22.50 | 1 | 14.30 |   |   | 20 | 21.10 | 4 | 28.60 |   |   | 19 | 22.60 | 5 | 20.00 |   |   |
| 2 | 7 | 6.90 | 0 | 0.00 |   |   | 7 | 7.40 | 0 | 0.00 |   |   | 6 | 7.10 | 1 | 4.00 |   |   |
| 4 | 1 | 1.00 | 0 | 0.00 |   |   | 1 | 1.10 | 0 | 0.00 |   |   | 1 | 1.20 | 0 | 0.00 |   |   |
| # mood disorders (current) d |  |  |   |   | 1.06 | 0.59 |   |   |   |   | 1.77 | 0.41 |   |   |   |   | 2.37 | 0.31 |
| 0 | 69 | 67.60 | 6 | 85.70 |   |   | 64 | 67.40 | 11 | 78.60 |   |   | 57 | 67.90 | 18 | 72.00 |   |   |
| 1 | 29 | 28.40 | 1 | 14.30 |   |   | 28 | 29.50 | 2 | 14.30 |   |   | 25 | 29.80 | 5 | 20.00 |   |   |
| 2 | 4 | 3.90 | 0 | 0.00 |   |   | 3 | 3.20 | 1 | 7.10 |   |   | 2 | 2.40 | 2 | 8.00 |   |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | End of treatment |   |   | 6-month follow-up |   |   | 12-month follow-up |  |  |
|  | Completers (n=102) | Missing (n=7) |   |   | Completers (n=95) | Missing (n=14) |   |   | Completers (n=84) | Missing (n=25) |  |   |   |
|  | # | % | # | % | *χ2* | *p* | # | % | # | % | *χ2* | *p* | # | % | # | % | *χ2* | *p* |
| # ETOH & SUD disorders (lifetime) d |  |  |   |   | 10.45 | 0.02 |   |   |   |   | 4.26 | 0.24 |   |   |   |   | 2.47 | 0.46 |
| 0 | 85 | 83.30 | 5 | 71.40 |   |   | 80 | 84.20 | 10 | 71.40 |   |   | 72 | 85.70 | 18 | 72.00 |   |   |
| 1 | 11 | 10.80 | 0 | 0.00 |   |   | 9 | 9.50 | 2 | 14.30 |   |   | 7 | 8.30 | 4 | 16.00 |   |   |
| 2 | 3 | 2.90 | 2 | 28.60 |   |   | 3 | 3.20 | 2 | 14.30 |   |   | 3 | 3.60 | 2 | 8.00 |   |   |
| 3 | 3 | 2.90 | 0 | 0.00 |   |   | 3 | 3.20 | 0 | 0.00 |   |   | 2 | 2.40 | 1 | 4.00 |   |   |
| # anxiety disorders (lifetime)d |  |  |   |   | 0.15 | 0.70 |   |   |   |   | 0.31 | 0.58 |   |   |   |   | 0.16 | 0.69 |
| 0 | 92 | 90.20 | 6 | 85.70 |   |   | 86 | 90.50 | 12 | 85.70 |   |   | 75 | 89.30 | 23 | 92.00 |   |   |
| 1 | 10 | 9.80 | 1 | 14.30 |   |   | 9 | 9.50 | 2 | 14.30 |   |   | 9 | 10.70 | 2 | 8.00 |   |   |
| # mood disorders (lifetime) d |  |  |   |   | 2.62 | 0.11 |   |   |   |   | 3.21 | 0.07 |   |   |   |   | 4.21 | 0.04 |
| 0 | 61 | 59.80 | 2 | 28.60 |   |   | 58 | 61.10 | 5 | 35.70 |   |   | 53 | 63.10 | 10 | 40.00 |   |   |
| 1 | 41 | 40.20 | 5 | 71.40 |   |   | 37 | 38.90 | 9 | 64.30 |   |   | 31 | 36.90 | 15 | 60.00 |   |   |
| Group |  |  |   |   | 3.48 | 0.18 |   |   |   |   | 0.18 | 0.92 |   |   |   |   | 1.02 | 0.60 |
| cGSH | 39 | 38.20 | 3 | 42.90 |   |   | 36 | 37.90 | 6 | 42.90 |   |   | 34 | 40.50 | 8 | 32.00 |   |   |
| CBT+ | 31 | 30.40 | 0 | 0.00 |   |   | 27 | 28.40 | 4 | 28.60 |   |   | 22 | 26.20 | 9 | 36.00 |   |   |
| DBT | 32 | 31.40 | 4 | 57.10 |   |   | 32 | 33.70 | 4 | 28.60 |   |   | 28 | 33.30 | 8 | 32.00 |   |   |
| Response |  |  |   |   | 0.06 | 0.81 |   |   |   |   | 0.13 | 0.72 |   |   |   |   | 0.58 | 0.45 |
| Early strong | 39 | 38.20 | 3 | 42.90 |   |   | 36 | 37.90 | 6 | 42.90 |   |   | 34 | 40.50 | 8 | 32.00 |   |   |
| Early weak | 63 | 61.80 | 4 | 57.10 |   |   | 59 | 62.10 | 8 | 57.10 |   |   | 50 | 59.50 | 17 | 68.00 |   |   |
|   | *m* | *sd* | *m* | *sd* | *F* | *p* | *m* | *sd* | *m* | *sd* | *F* | *p* | *m* | *sd* | *m* | *sd* | *F* | *p* |
| Age a | 38.51 | 13.13 | 34.00 | 7.59 | 0.80 | 0.37 | 38.32 | 13.30 | 37.57 | 9.81 | 0.04 | 0.84 | 37.96 | 12.96 | 39.08 | 12.79 | 0.14 | 0.71 |
| OBD frequency b  | 7.35 | 7.11 | 11.71 | 9.73 | 2.35 | 0.13 | 7.41 | 7.32 | 9.14 | 8.57 | 0.68 | 0.41 | 6.89 | 7.01 | 10.12 | 7.96 | 3.84 | 0.05 |
| OBE frequency b  | 9.55 | 11.23 | 15.86 | 13.59 | 2.02 | 0.16 | 9.71 | 11.41 | 11.64 | 11.83 | 0.35 | 0.56 | 9.01 | 11.02 | 13.12 | 12.40 | 2.53 | 0.12 |
| V frequency b  | 5.39 | 16.42 | 9.00 | 15.50 | 0.32 | 0.57 | 5.57 | 16.90 | 6.00 | 12.11 | 0.01 | 0.93 | 4.04 | 13.65 | 10.96 | 22.68 | 3.55 | 0.06 |
| Body Mass Index b  | 33.39 | 9.85 | 37.79 | 16.35 | 1.19 | 0.28 | 33.17 | 9.54 | 37.08 | 14.65 | 1.76 | 0.19 | 33.39 | 9.28 | 34.62 | 13.46 | 0.27 | 0.61 |
| EDE-16 total b  | 2.46 | 1.13 | 2.65 | 1.40 | 0.19 | 0.66 | 2.44 | 1.16 | 2.63 | 1.09 | 0.33 | 0.57 | 2.40 | 1.15 | 2.69 | 1.11 | 1.26 | 0.26 |
| GAF e | 60.21 | 10.97 | 61.14 | 7.69 | 0.05 | 0.83 | 60.09 | 11.23 | 61.43 | 6.96 | 0.19 | 0.67 | 61.12 | 11.20 | 57.40 | 8.71 | 2.33 | 0.13 |

*NB:* Theshold for Bonferroni corrected *p* = .05/69 = 7.25e-4 ; OBD = objective binge day; OBE = objective binge episode; V = vomiting; BED = Binge eating disorder; BN = Bulimia Nervosa; ETOH = Alcohol; SUD =- Substance use disorders; cGSH = continued Guided Self-Help; DBT = Dialectical Behavior Therapy, CBT+ = group and individual Cognitive Behavior Therapy; Eating Disorders Examination (EDE) (Fairburn, 2008); Global assessment of functioning (GAF) scores: 51-60, moderate impairment; 61-70, mild impairment; 71-80, slight impairment over the last year from the DSM IV TR (APA., 2000)

a Self-identified classification and options defined by the investigator.

b over the last month from the Eating Disorders Examination-16 (Fairburn, 2008)

c from the SCID II (First, Spitzer, Williams, & Gibbon, 1997)

d DSM-IV-TR (APA., 2000) diagnoses from Longitudinal Interview Follow-up Evaluation Psychiatric Status Ratings (Keller et al., 1987). This did not count eating disorder diagnoses. Current = last year; Lifetime = before the last year.

e Global assessment of functioning (GAF) scores: 51-60, moderate impairment; 61-70, mild impairment; 71-80, slight impairment over the last year from the DSM IV TR (APA., 2000)